BioCentury | Jan 13, 2020
Targets & Mechanisms

For $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD

Biogen acquired a clinical asset from Pfizer and will investigate its potential to normalize circadian rhythm to treat “sundowning” in Alzheimer’s disease and irregular sleep associated with Parkinson’s disease. Monday’s deal is Biogen’s second in...
BC Innovations | Feb 5, 2019
Distillery Therapeutics


INDICATION: Renal cancer In vitro and cell culture studies identified an aminothiazole-based negative allosteric modulator (NAM) of CSNK2 that could help treat renal cell carcinoma (RCC). Chemical synthesis and in vitro testing of aminothiazole analogs...
BC Week In Review | Jan 12, 2018
Company News

Exelixis, StemSynergy in CSNK1A activator deal

Exelixis Inc. (NASDAQ:EXEL) and StemSynergy Therapeutics Inc. (Miami, Fla.) partnered to discover and develop compounds targeting casein kinase 1 alpha (CSNK1A; CKI-alpha) to treat cancer. The partners will conduct preclinical and clinical studies of compounds...
BC Innovations | Aug 17, 2017
Translation in Brief

Stopping the invasion

A team from the Netherlands Cancer Institute (NKI) has identified a network of extracellular matrix proteins that drives glioblastoma invasiveness and a master switch -- interferon regulatory factor 3 (IRF3) -- that can turn it...
BC Innovations | Aug 16, 2017
Distillery Therapeutics


INDICATION: Brain cancer Cell culture studies suggest activating IRF3 or inhibiting its negative regulator CSNK2 could help treat glioblastoma multiforme (GBM). In mouse brain slices co-cultured with a patient-derived GBM cell line, vector-mediated constitutively active...
BC Innovations | Jul 18, 2017
Distillery Therapeutics


INDICATION: Colorectal cancer Patient sample, in vitro , cell culture and mouse studies identified a benzamide-based CSNK1A activator that could help treat Wnt signaling-driven colorectal cancer. In colorectal cancer patients, low tumor levels of CSNK1A were...
BC Innovations | Feb 28, 2017
Distillery Therapeutics


INDICATION: Huntington's disease (HD) Patient sample and mouse studies suggest inhibiting CSNK2A2 could help treat HD. Levels of CSNK2A2 were higher in striatal tissue samples from HD patients and striatal and gastrocnemius muscle tissue samples...
BC Innovations | Aug 4, 2016
Targets & Mechanisms

Cereblon ambition

Most anti-cancer strategies aim to block overactive proteins by directly inhibiting their activity, but a growing number of companies are developing ways to tag the proteins for destruction by recruiting the enzymes that shuttle them...
BC Week In Review | May 16, 2016
Company News

Hebrew University of Jerusalem, BioTheryX deal

The university’s Yissum Research Development Co. and BioTheryX partnered to develop and commercialize casein kinase 1 alpha ( CSNK1A ; CKI-alpha ) inhibitors to treat hematologic and solid malignancies. The collaboration will initially focus on subtypes of...
BC Innovations | Apr 16, 2015
Distillery Therapeutics

Therapeutics: Casein kinase 1α (CSNK1A; CK1-α)

Cancer INDICATION: Cancer In vitro and mouse studies suggest inhibiting CSNK1A and autophagy could help treat cancers expressing oncogenic Ras . In Ras-expressing human fibroblasts and colon cancer cells, siRNA targeting CSNK1A or a small molecule...
Items per page:
1 - 10 of 31